Immunoassay Market Overview | Leading players and Business Intelligence
The increasing incidence of chronic and infectious diseases,
technological advancements in immunoassay instruments and introduction
of novel automated systems, and growth in the biotechnology and
biopharmaceutical industries are some the major factors driving the
growth of this market.
According to the new market research report Immunoassay Market is expected to reach USD 27.15 Billion by 2023 from USD 20.19 Billion in 2018, at a CAGR of 6.1%.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=436
•
By platform, this market is classified into CLIAs, radioimmunoassays
(RIAs), colorimetric immunoassays (CIs), fluorescence immunoassays
(FIAs), and other platforms.
• On the basis product and service, this
market is classified into reagents and kits, analyzers, and software
and services. In 2017, the reagents and kits segment accounted for the
largest share of the immunoassays market.
• On the basis of
technology, the immunoassay market is segmented into ELISA, rapid tests,
western blotting, enzyme-linked immunospot (ELISPOT), immuno-PCR, and
other immunoassay technologies.
The immunoassays market is
consolidated in nature due to the presence of a large number of players.
Key players in the market include Abbott Laboratories (US), Roche
(Switzerland), Siemens (Germany), Danaher Corporation (US), DiaSorin
(Italy), Ortho Clinical Diagnostics (US), Thermo Fisher Scientific (US),
QIAGEN (Netherlands), Becton, Dickinson and Company (US), Bio-Rad
Laboratories (US), Merck (Germany), Agilent Technologies (US), Quidel
Corporation (US), PerkinElmer (US), Mindray (China), and Bio-Techne
Corporation (US).
The key strategies followed by most companies
in the immunoassay market are product launches and partnerships,
collaborations, & agreements. These strategies accounted for the
largest share of the overall growth strategies mapped from 2015 to 2018
(till March). Some of the leading players who adopted these strategies
include Roche (Switzerland), Abbott Laboratories (US), Danaher
Corporation (US), bioMérieux (France), and Sysmex Corporation (Japan).
In
2017, Roche was the leading player in the immunoassays market. This
position of the company can be attributed to its wide product portfolio,
which includes clinical chemistry and immunochemistry solutions,
molecular diagnostic products, tissue diagnostic instruments, reagents,
and kits. Under its flagship brand, Cobas, the company offers a variety
of IVD instruments, reagents, and kits that are widely used by end users
across the globe.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=436
Abbott
Laboratories accounted for the second-largest share of the immunoassay
market in 2017. With the acquisition of Alere, Inc. (US) in 2017, the
company was able to enhance its presence in the immunoassays market.
With the completion of this acquisition, Abbott strengthened its
diagnostics portfolio and established itself as a leading player in the
point-of-care testing and immunoassay market.
Comments
Post a Comment